We've created a starter pack so that you can follow members of the MRC Centre for Medical Mycology in one go! We'll be updating this pack as members join Bluesky! 🦋

bsky.app/starter-pack...

Subscribe to this list to keep up to date with all of the incredible research coming out of the CMM 🍄🔬👩‍🔬

Mycology 2025 Fungal Update: Mycology 2024 is a two-day conference which brings together the fungal community to discuss the latest updates in the world of medical mycology.

Discover the future of medical mycology!🌟

Join Fungal Update for #Mycology2025 to explore topics from the intersection of climate change and fungal disease to the future of point of care testing.🔬

Register below now! 👇
ow.ly/uICR50TaGjx

#FungalUpdate #MedicalMycology

Pulmonary Co-Infection of Pneumocystis jirovecii and Aspergillus species Abstract. In this multicenter study of 387 immunocompromised patients, 4.5% with invasive pulmonary aspergillosis (IPA) also had Pneumocystis jirovecii pne

🆕💫 Retrospective multicentre study
Pulmonary Co-Infection of Pneumocystis jirovecii and Aspergillus species #idsky
academic.oup.com/ofid/advance...

MDR-GNB infections remain a major global health challenge. With new diagnostics & antibiotics emerging, we’re at a crossroads.
Fantastic 🆕💫review about MDR GN by Dr. Nenad Macesic
Figures🌟 #idsky
www.thelancet.com/journals/lan...

Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria | Journal of Clinical Microbiology Rezafungin is a second-generation echinocandin that has shown activity against a range of Candida species including wild-type and azole- and echinocandin-resistant isolates (1–3). Rezafungin has improved chemical and biological properties that are distinct from other echinocandins. Most notably, the modified backbone of rezafungin leads to a stable chemical structure with reduced metabolism and degradation relative to other echinocandins. This results in a longer half-life, which allows for weekly dosing, improved tissue penetration, and reduced organ toxicity (4, 5). Less frequent dosing also results in high front-loaded exposure, which, along with good distribution to and penetration at infection sites may allow earlier mycological clearance from sites of infection with the potential to prevent the emergence of resistance (4, 6–10). Rezafungin was approved in 2023 by the United States Food and Drug Administration for the treatment of candidemia and invasive candidiasis based on clinical efficacy and safety data from the randomized Phase 2 STRIVE and Phase 3 ReSTORE clinical trials (10–12).

🆕💫 #JCM
Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria #IDXposts
@absteward.bsky.social
journals.asm.org/doi/abs/10.1...

a man in a suit and tie stands in front of a group of people and says there are dozens of us Alt: Tobias Fünke standing if front of a crowd in a brown suit, yelling "There are dozens of us. DOZENS!" while pointing to the sky

#IDSky Starter Packs (Updated 11/11/24)

IDSky 1 go.bsky.app/LnAQjdq
IDSky 2 go.bsky.app/JNfSvQT
IDSky 3 go.bsky.app/FeogT7o
IDSky 4 go.bsky.app/D1zxj4E
TxID go.bsky.app/95rzmLi
MedMycology go.bsky.app/8XGywEx

Let me know if I missed you! cc #MedSky

PhD position available in University of Exeter across Biosciences and the MRC Centre for Medical Mycology. The project will use chromatin genetics to investigate how pathogenic fungi adapt to their human host.